AB-1015 is under clinical development by Arsenal Biosciences and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase I drugs for Epithelial Ovarian Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AB-1015’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AB-1015 overview

AB-1015 is under development for the treatment of ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The therapeutic candidate comprises T cells which are genetically engineered to knockdown FAS and PTPN2 and to express chimeric antigen receptor (CAR) targeting antigens ALPG/P and MSLN. Knockdown of FAS and PTPN2 results in CAR T cells that are resistant to FAS-mediated apoptosis and enhanced in vivo expansion. The drug candidate is administered through intravenous route.

Arsenal Biosciences overview

Arsenal Biosciences is a cell therapy company that discovers, develops and commercializes immune cell therapies to treat cancer. The company utilizes its synthetic biology compositions made up of PrimeR logic gates, CARchitecture acquired gene expression controls, and CellFoundry mediated nonviral manufacturing to develop cell therapy product candidates. It was funded by Kleiner Perkins, Westlake Village Biopartners, Euclidean Capital, Osage University Partners and UCSF foundation investment company. The company works in collaboration with Bristol Myers Squibb Co to evaluate T cell therapies for the treatment of solid tumors. Arsenal Biosciences is headquartered in South San Francisco, California, the US.

For a complete picture of AB-1015’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.